Palleon Pharmaceuticals announced presentations on HLX316/E-688 at the 2026 AACR Annual Meeting in San Diego (April 17-22).
HLX316/E-688 is a first-in-class B7-H3-targeted sialidase from the EAGLE platform, designed to enhance innate and adaptive anti-tumor immunity by desialylating tumor cells.
Oral presentation: 'A First-in-Class Human Sialidase-Armed Anti-B7-H3 Antibody that Enhances Innate and Adaptive Antitumor Immune Responses' on April 19, 3:00-4:30 PM PT (Abstract ID:
7158).
Poster presentation on April 22, 9:00 AM-12:
00 PM PT in the Experimental and Molecular Therapeutics session.
Developed in China by Shanghai Henlius Biotech; NMPA cleared Phase 1 IND for advanced/metastatic solid tumors.
Announced April 2, 2026 via Business Wire.1
Sources:
1. https://www.businesswire.com/news/home/20260402473501/en/Palleon-Pharmaceuticals-to-Present-on-Development-of-HLX316E-688-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting